[Form 4] Sangamo Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 highlights – Zillow Group, Inc. (ZG, Z): Co-Executive Chairman, President and Co-Founder Lloyd D. Frink reported paired option exercises and open-market sales on 22-23 Jul 2025.

• Options exercised: 52,866 shares on 7/22/25 and 27,134 shares on 7/23/25 at a fixed $22.41 strike (grants dated 05/18/16, expiring 03/28/26).
• Shares sold: Exactly the same totals (80,000 shares) were sold under a 10b5-1 plan at weighted-average prices of $80.25, $80.60 and $81.24.
• Holdings after transactions: 2,383,189 Class C shares held directly and 797,765 shares held indirectly through the Frink Descendants’ Trust.
• Ownership status: Frink remains a director, executive officer and co-founder; filing made individually.

No Class A or Class B activity was reported. The trades convert in-the-money options to cash without changing Frink’s overall direct share count materially.

Positive

• None.

Negative

• Approximately 80,000 shares sold by a top executive could be interpreted as reduced near-term confidence, despite being under a 10b5-1 plan.

Insights

Equity Analyst

TL;DR: Insider exercised 80k options and immediately sold, monetising gain; net share count unchanged, sentiment mildly negative.

Frink’s exercise-and-sell suggests liquidity taking rather than incremental investment. The ~80k share sale is <1 % of his 2.38 M direct stake, so limited structural impact, yet insider selling near $80—4× the $22.41 strike—may be viewed as a short-term confidence check. No new options granted. The 10b5-1 plan reduces signal noise, but investors often discount when multiple sales occur at multi-year highs. Overall, the filing is moderately negative for sentiment but not financially material to Zillow.

Corporate Governance Specialist

TL;DR: Routine 10b5-1 cash-out; governance risk low, market impact minimal.

Use of a pre-arranged 10b5-1 plan aligns with best-practice, limiting potential misuse of insider knowledge. Exercising options close to expiry and selling equal shares keeps exposure level steady, signalling portfolio rebalancing rather than exit. Remaining holdings and board role preserve alignment with shareholders. I classify the event as low governance risk and largely non-impactful.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Davis Gregory D

(Last) (First) (Middle)

C/O SANGAMO THERAPEUTICS, INC.

501 CANAL BLVD.

(Street)

RICHMOND CA 94804

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SANGAMO THERAPEUTICS, INC [ SGMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Research & Technology

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2025		F		6,708(1)	D	$0.4798	201,945(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on July 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on July 22, 2025 of $0.4798/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

2. Includes: (a) 12,042 shares resulting from the July 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 37,500 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 6,065 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

	/s/ Scott Willoughby, Attorney-in-Fact	07/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Zillow (ZG) shares did Lloyd Frink sell in July 2025?

He sold a total of 80,000 Class C shares in two tranches on 22-23 Jul 2025.

At what prices were the Zillow shares sold?

Weighted-average sale prices were $80.25, $80.60 and $81.24, per the Form 4 footnotes.

Did the executive exercise stock options before selling?

Yes, he exercised 52,866 options on 7/22/25 and 27,134 options on 7/23/25 at a $22.41 strike.

How many Zillow shares does Frink still own after the transactions?

He holds 2,383,189 Class C shares directly and 797,765 indirectly through a family trust.

Was the sale made under a 10b5-1 trading plan?

Yes, the filing states the sales were executed under a Rule 10b5-1 plan adopted 11 Dec 2024.